Bolt Biotherapeutics (BOLT) Operating Expenses (2020 - 2026)

For the trailing twelve months through Jun 30, 2026, Operating Expenses at Bolt Biotherapeutics was $35.46 million, down 39.7% year-over-year; for FY2025, it came in at $43.81 million, down 45.7% from FY2024.

• Annual Operating Expenses has declined for three consecutive years, with a five-year compound annual growth rate of -2.4% (FY2020 to FY2025).
• In prior years, Bolt Biotherapeutics' Operating Expenses was $80.74 million in FY2024 (-4.0%), $84.07 million in FY2023 (-12.5%), $96.05 million in FY2022 (+2.1%) and $94.05 million in FY2021 (+90.3%).
• Quarterly Operating Expenses has run from a low of $7.63 million in Q1 2026 to a high of $27.58 million in Q4 2021 over five years.
• On a year-over-year basis, Operating Expenses has declined in each of the last eight quarters, with an average decline of 35.7% over the last eight quarters.
• The strongest year-over-year quarter for Operating Expenses in the past five years was Q3 2021, with growth of 95.7%; the weakest was Q2 2025, with a decline of 53.9%.
• According to Business Quant data, Operating Expenses for the three prior quarters was $7.63 million (Q1 2026), $9.59 million (Q4 2025) and $9.87 million (Q3 2025).